Brief: Bioxyne Reports Qtrly Revenue A$17.2 Mln
28/01/2026 01:38
Jan 28 (Reuters) - Bioxyne Ltd BXN.AX: REPORTS A$17.2 MILLION QUARTERLY REVENUE Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal